Characterization of Nevirapine Resistance Mutations in Women with Subtype A Vs. D HIV-1 6-8 Weeks after Single-Dose Nevirapine (HIVNET 012)

Susan H. Eshleman, Laura A. Guay, Anthony Mwatha, Elizabeth R. Brown, Shawn P. Cunningham, Philippa Musoke, Francis Mmiro, J. Brooks Jackson

Research output: Contribution to journalArticle

97 Scopus citations

Abstract

Objective: To compare the number and type of nevirapine (NVP) resistance mutations detected in Ugandan women with subtype A vs. D HIV-1 infection after single-dose NVP prophylaxis. Design: In the HIVNET 012 trial, a higher rate of NVP resistance (NVPR) was seen in women with subtype D than A after single-dose NVP. In this study, the number and type of NVPR mutations detected 6-8 weeks after NVP were compared in women with subtypes A vs. D. Methods: Plasma samples were available for 282 (92%) of 306 women who received NVP in HIVNET 012. Samples were analyzed with the ViroSeq HIV-1 Genotyping System (Applied Biosystems, Foster City, CA). Subtyping was performed by phylogenetic analysis of pol region sequences. Results: Results were obtained for 279 women, including 147 with subtype A, 98 with subtype D, 6 with subtype C, and 28 with recombinant HIV-1. NVPR mutations were detected in 70 (25%) of 279 women. NVPR was more common in women with subtype D vs. A (35.7 vs. 19%, P = 0.0035). Complex patterns of NVPR mutations were detected in both subtypes. Among women with NVPR, 43% of women with subtype A and 46% of women with subtype D had ≥2 NVPR mutations. The mean number and pattern of NVPR mutations detected in women with subtypes A and D were similar. Conclusions: This study confirms a higher rate of NVPR in women with subtype D than A and further defines the pattern of NVPR mutations that emerge 6-8 weeks after single-dose NVP prophylaxis in these subtypes.

Original languageEnglish (US)
Pages (from-to)126-130
Number of pages5
JournalJournal of Acquired Immune Deficiency Syndromes
Volume35
Issue number2
DOIs
StatePublished - Feb 1 2004

Keywords

  • Drug resistance
  • HIV-1
  • Nevirapine
  • Subtype
  • Uganda

Fingerprint Dive into the research topics of 'Characterization of Nevirapine Resistance Mutations in Women with Subtype A Vs. D HIV-1 6-8 Weeks after Single-Dose Nevirapine (HIVNET 012)'. Together they form a unique fingerprint.

  • Cite this